Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.24 (
mitogen-activated protein kinase
)
95,810
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A previous genome-wide methylation array for colorectal cancer (CRC) identified aberrant promoter methylation of
eyes absent 4
(
EYA4
). However, the correlations between
EYA4
methylation and gene expression, the role played by EYA4 protein in colorectal carcinogenesis, and results of the gene-enrichment and functional annotation analysis have not yet been established. We analyzed the
EYA4
methylation status and found
EYA4
promoter methylation in CRC cell lines (100%), CRC tissues (93.5%) and advanced adenoma tissues (50.7%), compared with normal mucosa (32.6%). There was a significant inverse correlation between
EYA4
methylation and expression.
EYA4
transfection led to inhibition of cell proliferation in colony assays and xenograft studies. On performing the gene-enrichment and functional annotation analysis, we observed that the differentially expressed genes have been associated with the Wnt and
MAPK
signaling pathways. Our results demonstrate that
EYA4
is under epigenetic regulation in CRC. It is a candidate tumor suppressor gene that acts by inducing up-regulation of DKK1 and inhibiting the Wnt signaling pathway. In addition,
EYA4
methylation may be identified in stool samples and it serves as a potential stool biomarker for detection of advanced adenoma and CRC.
...
PMID:EYA4 Acts as a New Tumor Suppressor Gene in Colorectal Cancer. 2562 Feb 32